Acamprosate Calcium

證據等級: L5

預測適應症: 0 個

Acamprosate Calcium: Evaluation Report — Insufficient Data for Repurposing Analysis

One-Sentence Summary

Acamprosate Calcium is a drug with no approved license in Taiwan, and its original indication is not documented in this Evidence Pack. The TxGNN model returned no predicted indications for this candidate, making a standard repurposing analysis impossible at this time. Due to multiple blocking data gaps, this report serves as a triage summary recommending data remediation before further evaluation.

Quick Overview

Item	Content
Original Indication	Not available in this Evidence Pack
Predicted New Indication	No TxGNN predictions returned
TxGNN Prediction Score	N/A
Evidence Level	N/A (no predictions available)
Taiwan Market Status	Not marketed (未上市)
Number of Licenses	0
Recommended Decision	Hold

Why Analysis Cannot Proceed

The Evidence Pack for this candidate contains two blocking gaps that prevent standard evaluation:

No mechanism of action (MOA) data. The DrugBank query returned one result (query log ID 3), but MOA details were not populated in the drug.original_moa field. Without understanding how this drug works, it is impossible to assess whether its mechanism could plausibly extend to any new indication.

No TxGNN predicted indications. The predicted_indications array is empty. This may result from failed drug-to-DrugBank-ID mapping (the drugbank_id field is null), which would prevent the KG and DL prediction pipelines from producing candidates. Without at least one predicted indication, the core purpose of the repurposing evaluation cannot be fulfilled.

No Taiwan regulatory history. With zero licenses on record, there is no approved indication text, dosage form, or patient population to anchor the analysis.

Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or drug interaction data were available in this Evidence Pack.

Conclusion and Next Steps

Decision: Hold

Rationale: The absence of TxGNN predictions — most likely caused by a missing DrugBank ID — means no repurposing direction exists to evaluate. Combined with a complete absence of MOA data and regulatory history, there is no analytical foundation on which to build a recommendation.

To proceed, the following is needed:

[Blocking] Resolve DrugBank ID mapping — The drugbank_id field is null. Query DrugBank by drug name (“acamprosate calcium”) to retrieve the correct ID (e.g., DB00659), then rerun the KG and DL prediction pipelines to generate predicted_indications.
[Blocking] Retrieve MOA data — Use the DrugBank API or DrugBank web entry to populate mechanism of action, pharmacodynamics, and drug categories.
[High] Retrieve safety data — Download and parse the package insert (if available in any jurisdiction where this drug is approved) to populate key_warnings and contraindications.
[Follow-up] Resubmit Evidence Pack — Once DrugBank ID is resolved and predictions are generated, a full v5 report can be produced.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.